Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/109426
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wedzicha, Jadwiga A. | - |
dc.contributor.author | Agustí García-Navarro, Àlvar | - |
dc.contributor.author | Donaldson, Gavin | - |
dc.contributor.author | Chuecos, Ferran | - |
dc.contributor.author | Lamarca, Rosa | - |
dc.contributor.author | Garcia Gil, Esther | - |
dc.date.accessioned | 2017-04-05T15:06:05Z | - |
dc.date.available | 2017-04-05T15:06:05Z | - |
dc.date.issued | 2016-05-09 | - |
dc.identifier.issn | 1176-9106 | - |
dc.identifier.uri | http://hdl.handle.net/2445/109426 | - |
dc.description.abstract | We investigated the effect of the long-acting muscarinic antagonist aclidinium bromide on chronic obstructive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled,parallel-group Phase III studies of 3-6 months' duration. Data were pooled from the aclidinium 400 μg twice-daily (BID) and placebo arms (N = 2,521) and stratified by Global initiative for chronic Obstructive Lung Disease (GOLD) group (A, B, C and D). Results showed that fewer patients experienced 1 exacerbation with aclidinium (any severity: 12.5%; moderate to severe: 10.9%) compared with placebo (any severity: 15.7%; moderate to severe: 13.3%) and the odds of experiencing 1 exacerbation of any severity were reduced in patients receiving aclidinium (odds ratio = 0.78, p = 0.039). Furthermore, aclidinium reduced the rate of exacerbations compared with placebo (any severity: rate ratio = 0.79, p = 0.026; moderate to severe: 0.80, p = 0.044). The time to first exacerbation of any severity was delayed with aclidinium compared with placebo (hazard ratio = 0.79, p = 0.026) and there was a numerical delay in time to first moderate-to-severe exacerbation. Finally, the effects of aclidinium on exacerbations versus placebo were greater in patients in GOLD Groups B and D; however, it is of note that only 10.7% of patients were classified in Group A or C. In summary, the results indicate that aclidinium 400 μg BID reduces the frequency of COPD exacerbations compared with placebo and that these effects are greater in symptomatic patients. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3109/15412555.2016.1170111 | - |
dc.relation.ispartof | International Journal of Chronic Obstructive Pulmonary Disease, 2016, vol. 13, num. 6, p. 669-676 | - |
dc.relation.uri | https://doi.org/10.3109/15412555.2016.1170111 | - |
dc.rights | cc-by-nc (c) Wedzicha et al., 2016 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Malalties pulmonars obstructives cròniques | - |
dc.subject.classification | Malalties del pulmó | - |
dc.subject.other | Chronic obstructive pulmonary diseases | - |
dc.subject.other | Pulmonary diseases | - |
dc.title | Effect of aclidinium bromide on exacerbations in patients with moderate to severe COPD: a pooled analysis of five Phase III, randomized, placebo-controlled studies | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 668953 | - |
dc.date.updated | 2017-04-05T15:06:05Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27159613 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
668953.pdf | 1.64 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License